Avid Bioservices Inc (CDMO)

[biopharm]

I wonder if Dr. Parsa realized the potential of PS Targeting

Could have the late Dr. Andrew Parsa also been on the fast track to quickly learning re: PS Targeting ?

This becomes a little shocking. Now, Dr. Wolchok has been working with platforms from the late (both young..) Dr. Philip Thorpe / Dr. Andrew Parsa.

Checkpoint Antibody Platform
..
..
..

Agenus has six preclinical programs that aim to produce monoclonal antibodies that block or activate specific checkpoint target receptors (GITR, OX40, PD-1, CTLA-4, TIM-3, and LAG-3). 4-Antibody has been working on these targets for more than three years, in collaboration with one of the world’s most prestigious and powerful academic groups focused on the interactions between cancer and the immune system, Ludwig Cancer Research and in particular with the leader of the Ludwig collaborative laboratory at Memorial Sloan Kettering Cancer Center, Jedd Wolchok, MD, PhD. Dr. Wolchok is recognized as one the true leaders in the emerging field of immuno-oncology. Agenus has now advanced three CPM candidates into Investigational New Drug-enabling development and we anticipate having several antibodies in clinical trials in the next two years.

We are uniquely positioned at the forefront of cancer immunotherapy with a portfolio of innovative approaches, which include checkpoint modulators, personalized anti-cancer vaccines, and powerful adjuvants.
..
..

http://www.agenusbio.com/science/checkpoint.php

http://www.agenusbio.com/activities/leadership.php